WHO Antiretroviral Therapy Guidelines 2010 and Impact of Tenofovir on Chronic Kidney Disease in Vietnamese HIV-Infected Patients

Daisuke Mizushima1,2*, Junko Tanuma1, Fumihide Kanaya1, Takeshi Nishijima1,2, Hiroyuki Gatanaga1,2, Nguyen Tien Lam3, Nguyen Thi Hoai Dung3, Nguyen Van Kinh3, Yoshimi Kikuchi1, Shinichi Oka1,2*

1 AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan, 2 Center for AIDS Research, Kumamoto University, Kumamoto, Japan, 3 National Hospital of Tropical Diseases, Hanoi, Vietnam

Abstract

Objective: The 2010 WHO antiretroviral therapy (ART) guidelines have resulted in increased tenofovir use. Little is known about tenofovir-induced chronic kidney disease (CKD) in HIV-infected Vietnamese with mean body weight of 55 kg. We evaluated the prevalence and risk factors of CKD in this country.

Design: Cross-sectional study was performed.

Methods: Clinical data on HIV-infected Vietnamese cohort were collected twice a year. To evaluate the prevalence of CKD, serum creatinine was measured in 771 patients in October 2011 and April 2012. CKD was defined as creatinine clearance less than 60 ml/min at both time points. Multivariate logistic regression was used to determine the factors associated with CKD.

Results: Tenofovir use increased in Vietnam from 11.9% in April 2011 to 40.3% in April 2012. CKD was diagnosed in 7.3% of which 7% was considered moderate and 0.3% was severe. Multivariate analysis of October-2011 data identified age per year-increase (OR: 1.229, 95%CI, 1.170-1.291), body weight per 1 kg-decrement (1.286, 1.193-1.386), and tenofovir use (2.715, 1.028-7.168) as risk factors for CKD.

Conclusions: Older age, low body weight and tenofovir use were independent risk factors for CKD in Vietnam. Further longitudinal study is required to evaluate the impact of TDF on renal function in Vietnam and other countries with small-body weight patients.

Introduction

Advances in antiretroviral therapy (ART) had turned HIV/AIDS into a chronic disease [1-5]. As a consequence of living longer, chronic kidney disease (CKD) has become an important cause of morbidity and mortality in HIV-infected patients [1,3-5]. Several studies have reported increased prevalence of CKD, ranging from 4.9% to 8.4% in such patients [6-9]. In addition to the established risk factors, such as aging, diabetes mellitus (DM) and hypertension [2,10], other factors related to the virus itself and to the treatment [e.g., exposure to tenofovir (TDF), a commonly used antiretroviral (ARV)], are thought to be related to nephrotoxicity in HIV-infected patients [2,11,12].

To date, the benefit of TDF first line treatment is considered to outweigh the risk of TDF-induced nephrotoxicity. A recent meta-analysis study has reported that the use of TDF is associated with a statistically significant though only modest renal dysfunction, and recommended no restriction of TDF use when regular monitoring of renal function and serum phosphate levels is impractical [13]. Furthermore, the 2010 WHO guidelines for ART in adults and adolescents recommended TDF as part of the first line regimens (URL: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf).

However, several studies have reported that low body weight is an independent risk factor for TDF-associated nephrotoxicity and might lead to potentially higher risk for larger drug exposure and thus, more severe toxicity [14-17]. Under such
scenario, regional prevalence of CKD may influence the approach to screening and monitoring of HIV-infected patients initiated on ART. In particular, most nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), such as TDF and 3TC/FTC, are excreted by the kidney and may require dose adjustment in individuals with reduced glomerular filtration rate (GFR), and may require more intensive monitoring in patients with pre-existing CKD.

Following the 2010 WHO guidelines, the use of TDF has been increasing rapidly in Vietnam, where patients are more likely to have smaller body weight compared to Caucasians. At this stage, little is known about CKD among Vietnamese HIV-infected patients. In this context, it is important to determine the prevalence of CKD and its risk factors including TDF exposure and low body weight in this region. The present study was conducted to evaluate the above factors in Vietnamese HIV-infected patients.

Methods

Study design

We performed a cross-sectional study with an observational single-center cohort of Vietnamese HIV-infected patients on ART. This cohort was established since 2007 at the National Hospital of Tropical Disease in Hanoi, one of the largest outpatient clinics for HIV-infected-patients in Vietnam. Clinical data are collected twice a year (in April and October) in this cohort. The population of this cohort comprised HIV-infected patients on ART aged more than 17 years. To evaluate CKD in this group, serum creatinine had been examined since October 2011. Serum creatinine was measured in October 2011 and April 2012. Patients whose creatinine was not obtained at both time points were excluded from the study. Other clinical data were collected twice a year (in April and October) as well. The study was approved by the Human Research Ethics Committee of National Hospital of Tropical Disease and Hanoi city. Each patient included in this study provided a written informed consent for the clinical and laboratory data to be used for publication. The study was conducted according to the principles expressed in the Declaration of Helsinki.

Measurements

Data included demographic variables (height, weight, sex and age); a complete history of ART; use of cotrimoxazole; CD4 cell count (cell/mm$^3$, measured by flow cytometry); plasma HIV-RNA (copies/ml, measured by the Roche COBAS TaqMan HIV monitor assay); serum creatinine (mg/dl, measured by Jaffe method); date of HIV diagnosis and other comorbidities. CKD was defined as creatinine clearance (CCL) estimated by the Cockcroft-Gault formula of <60 ml/min at October 2011 and April 2012 (6 months apart). Renal dysfunction at each time point was also classified into five stages according to the guidelines of the National Kidney Foundation [18]: normal renal function: CCL ≥90 ml/min; mild renal dysfunction, CCL between 60-89 ml/min; moderate, CCL 30-59 ml/min; severe renal dysfunction, CCL 15-29 ml/min; and renal failure or dialysis, with CCL of <15 ml/min.

Statistical analysis

Statistical analysis included descriptive (mean and standard deviation), univariate and multivariate analyses. Absolute and relative frequencies were utilized for continuous and categorical variables, respectively. To evaluate the association between CKD and categorical variables, the chi-square test or Fisher exact test was applied as required. Independent T test or one-way analysis of variance (ANOVA) was used to compare mean values of normally distributed data and the Mann Whitney test or Kruskal-Wallis test for parameters with skewed data distribution. Variables significantly associated with renal dysfunction in univariate analysis (p<0.05) were entered into multivariate analysis. Logistic regression was used to determine the factors associated with CKD in univariate and multivariate analyses. Statistical significance was defined at two-sided p value <0.05. We used the odds ratio (OR) and 95% confidence interval (95% CI) to estimate the association of each variable with renal dysfunction. All statistical analyses were performed with The Statistical Package for Social Sciences ver. 17.0 (SPSS, Chicago, IL).

Results

Patients on TDF

The percentage of TDF use in our cohort increased from 11.9% in April 2011 to 40.3% in April 2012. In contrast, stavudine (d4T) use decreased from 37.8% in April 2011 to 14.6% in April 2012. The patterns of use of TDF and d4T well reflected the recommendation of the 2010 WHO ART guidelines; recommendation for the use of TDF or zidovudine (AZT) and phasing out of d4T.

Prevalence of CKD and renal dysfunction at each time point

To determine the prevalence of CKD, serum creatinine was measured in 771 patients in October 2011 and April 2012. CKD was diagnosed in 56 (7.3 %) patients and classified as moderate in 54 and severe in 2 (Table 1). The number of patients with moderate and severe renal dysfunction increased from 74 (9.6%) in October 2011 to 111 (14.4%) in April 2012. The data of serum creatinine by CKD stage are shown in Table 1.

Baseline demographics and laboratory data

Table 2 compares the baseline demographics and clinical variables of patients with or without CKD for the data of October 2011. Patients with CKD were significantly older, more likely to be diabetic females treated with TDF and lopinavir boosted with ritonavir, and of significantly lower body weight with higher serum creatinine, and with history of AIDS-defining disease, compared to those without CKD. CD4 count, HIV RNA viral load, and duration of ART were not significantly different between the two groups. The mean CD4 count was >300/mm$^3$ and the mean HIV RNA load was <100 copies/ml in both groups.
Table 1. Prevalence of CKD and renal function at two time points in 771 HIV-infected Vietnamese on ART.

| Renal function | CKD Oct 2011 | CKD Apr 2012 |
|----------------|--------------|--------------|
| Normal         | 90 or more   | 178 (23.0)   | 159 (20.6)   |
| Mild reduction | 60-89        | 519 (67.4)   | 501 (65.0)   |
| Moderate reduction | 30-59    | 72 (9.3)     | 108 (14.0)   |
| Severe reduction| 15-29        | 2 (0.3)      | 3 (0.4)      |
| Renal failure   | less than 15 | 0            | 0            |

Renal dysfunction was classified according to the guidelines of the National Kidney Foundation (18).

CKD was defined as GFRs of <60 ml/min at both time points (October 2011 and April 2012).

CKD; chronic kidney disease, ART; antiretroviral therapy.

Table 2. Baseline demographics and laboratory data of 771 patients measured at October 2011.

| Variables                        | Entire group | CKD (+) | CKD(-) | P value |
|----------------------------------|--------------|---------|--------|---------|
| Number of patients               | 771          | 56 (7.3%) | 715 (92.7%) |         |
| Age, years                       | 36.4±7.86    | 46.5±11.5 | 35.6±9.9  | <0.001  |
| Female, n (%)                    | 296 (38.4%)  | 36 (46.3%) | 260 (38.4%) | <0.001  |
| Body weight, kg                  | 55.0±8.4     | 57.4±6.3  | 55.6±8.2  | <0.001  |
| Diabetes mellitus, n (%)         | 32 (4.2%)    | 21 (26.4%) | 11 (1.5%)  | <0.001  |
| Serum creatinine, mg/dl          | 0.95±0.15    | 1.11±0.22 | 0.94±0.13 | <0.001  |
| CD4+ count, μl                   | 349.0±202.8  | 337.0±215.2 | 349.9±201.9 | 0.684  |
| HIV RNA, log10 copies/ml         | 1.79±0.52    | 1.80±0.47  | 1.79±0.52 | 0.833   |
| Duration of ART, years           | 1.34±1.54    | 1.69±1.96  | 1.32±1.51 | 0.083   |
| Use of TDF, n (%)                | 171 (22.2%)  | 23 (31.3%) | 148 (20.7%) | <0.001  |
| Use of Lopinavir, n (%)          | 97 (12.6%)   | 33 (42.2%) | 64 (9.1%)  | 0.013   |
| Use of cotrimoxazole, n (%)      | 171 (22.2%)  | 18 (23.2%) | 153 (21.4%) | 0.062   |
| AIDS defining disease, n (%)     | 69 (9.8%)    | 10 (13.9%) | 59 (8.3%)  | 0.015   |

Data are means±SD or n (%).

CKD; chronic kidney disease, ART; antiretroviral therapy, TDF; tenofovir.

doi: 10.1371/journal.pone.0079885.s002

Factors associated with CKD

Univariate analysis identified older age per year-increase, female sex, body weight per 1 kg-decrement, use of TDF, use of lopinavir boosted with ritonavir, diabetes mellitus, and AIDS-defining diseases as factors significantly associated with CKD. After adjustment by multivariate analysis, older age per year-increase (OR=1.229; 95%CI, 1.170-1.291; p<0.001), body weight per 1 kg-decrement (OR=1.286; 95%CI, 1.193-1.386; p<0.001), and use of TDF (OR=2.715; 95%CI, 1.028-7.168; p=0.044) were associated significantly with CKD (Table 3).

Discussion

We documented in the present study the prevalence of CKD and the associated risk factors in our Vietnamese cohort. CKD was identified in 7.3% of the patients between October 2011 and April 2012. Although severe renal dysfunction was observed in only 2 cases, we consider this finding quite alarming in our study setting, since it is more than double that reported in a previous study (3.1%) on the prevalence of CKD among Vietnamese healthy volunteers aged more than 40 years [19]. Our cohort comprised relatively younger and stable patients on ART with a mean age of 36.4 years.

In addition to the high prevalence of CKD, a striking finding in this study was that TDF use has increased steeply since the 2010 WHO ART guidelines that recommended the use of TDF. TDF use was also an independent risk for CKD in Vietnamese, in addition to lower body weight. We reported previously that Japanese patients with small body weight (<59 kg) treated with TDF were at high risk of renal dysfunction [16], whereas those with body weight of >67 kg had negligible risk, similar to the patients reported by Cooper et al [13]. One experimental study of rhesus macaques also reported that TDF-associated nephrotoxicity was dose-dependent [20]. The mean body weight of the patients enrolled in the present study was 55 kg, which is about 30 kg less than that of American males of similar age (88 kg) (URL: http://www.cdc.gov/nchs/data/nhsr/nhsr010.pdf). To prevent TDF-related CKD in patients with a small body weight, the efficacy and safety of low-dose TDF adjusted to low body weight should be evaluated in a clinical trial.

One study argued that the initial decline in eGFR following the commencement of TDF therapy stabilized later after the first 6 months [21]. However, whether or not the initial decline stabilizes later in patients with low body weight remains to be documented in a longitudinal study of our cohort. It is true that the future risk of TDF-related CKD is still uncertain. In this study, almost all patients who experienced renal dysfunction continued the same ART regimen because renal dysfunction was relatively moderate as shown in Table 1. Although one severe case showed improvement of renal function after cessation of TDF, normalization of renal function after...
withdrawal of TDF was reported to be incomplete in some cases [22]. Previous studies recommended dose reduction of drugs that are cleared by the kidney, such as lamivudine and TDF, when CrCl falls below 50 ml/min [23], to avoid further worsening of renal dysfunction. Early detection of eGFR decline is important for switching from TDF to AZT or abacavir to preserve renal function. Despite those concerns, however, there is no doubt that TDF is still an important drug with enough anti-HIV potency and less mitochondrial toxicity among NRTIs. In this regard, serum creatinine should be monitored even in resource-limited situations.

Furthermore, another study that compared patients with or without TDF use depicted that TDF was more likely to be used relatively high because injecting drug use is one of the main routes of infection in Vietnam. We are adding data for a longitudinal study on TDF toxicity in our cohort. Lastly, the Modification of Diet in Renal Disease formula (MDRD) or Chronic Kidney Disease Epidemiology Collaboration (CKD-epi) is commonly used for evaluation of renal function at present ([24-26]), however, the racial coefficient for Vietnamese is currently not available. In addition, serum creatinine was measured by the Jaffe method in our study, which is difficult to apply to MDRD or CKD-EPI since those formulations are based on measurement of serum creatinine by the more widely used enzymatic method. For this reason, our study utilized CrCl to assess renal function.

Despite these limitations, the results of the present study call for attention to active pharmacovigilance of TDF. The results identified TDF exposure as a significant and independent risk for CKD in Vietnam, although the duration of TDF use is still relatively short. Further longitudinal study is required to evaluate the impact of TDF on renal function in Vietnam and other countries with small-body weight patients.

Supporting Information

Table S1. Median and inter-quartile range of serum creatinine of 771 patients at October 2011 and April 2012. (DOCX)

Table S2. Baseline (October 2011) demographics and laboratory data of 771 patients with or without TDF use in whom serum creatinine was measured at October 2011 and April 2012. (DOC)

Acknowledgements

The authors thank Ms. Keiko Saito and Ms. Nguyen Thi Huyen for the excellent assistance. The authors also thank all the clinical staff at the National Hospital of Tropical Diseases for their help in the completion of this study.

Author Contributions

Conceived and designed the experiments: DM TN HG SO. Performed the experiments: NL ND NK YK. Analyzed the data: DM TN FK. Contributed reagents/materials/analysis tools: YK HG. Wrote the manuscript: DM TN HG SO.

References

1. Wyatt CM, Winston JA, Malvestutto CD, Fishbein DA, Barash I et al. (2007) Chronic kidney disease in HIV infection: an urban epidemic. AIDS 21: 2101-2103. doi:10.1097/QAD.0b013e3282ef1bb4. PubMed: 17885301.
2. Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P et al. (2007) Chronic renal failure among HIV-infected patients. AIDS 21: 1119-1127. doi:10.1097/QAD.0b013e3280774ce. PubMed: 17502722.
3. Paella FJ Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC et al. (2006) Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 43: 27-34. doi:10.1097/01.qai.000023310.90484.16. PubMed: 16878047.
4. Michaels SH, Clark R, Kissinger P (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 339: 405-406. doi:10.1056/NEJM199808063390612. PubMed: 9696654.
5. Gardner LI, Klein RS, Szczesn LA, Philips RM, Tashima K et al. (2003) Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr 34: 320-330. doi:10.1097/00126334-200311010-00011. PubMed: 14600579.
6. Delli EK, Thibault R, Bonnet F, Lawson-Ayayi S, Dupon M et al. (2010) Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med 11: 308-317. doi:10.1111/j.1468-1293.2009.00780.x. PubMed: 20002500.
7. Overton ET, Nurutdinova D, Freeman J, Seyfried W, Mody KE (2009) Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 50: 65-72. doi:10.1097/QAI.0b013e31818547f9. PubMed: 19076340.
8. Lucas GM, Lau B, Atta MG, Fine DM, Keruly J et al. (2008) Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis 197: 1548-1557. doi:10.1086/587994. PubMed: 18422458.
9. Menezes AM, Torelly J Jr., Real L, Bay M, Poeta J et al. (2011) Prevalence and risk factors associated to chronic kidney disease in HIV-infected patients on HAART and undetectable viral load in Brazil. PLOS ONE 6: e26042. doi:10.1371/journal.pone.0026042. PubMed: 22022501.
10. Crum-Cianflone N, Ganesan A, Teneza-Mora N, Riddle M, Medina S et al. (2010) Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDs 24: 353-360. doi:10.1089/apc.2009.0326. PubMed: 20515419.

11. Mocroft A, Kirk O, Reiss P, de Wit S, Sedlacek D et al. (2010) Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24: 1667-1678. doi:10.1097/QAD.0b013e328339fe53. PubMed: 20523203.

12. Barrios A, García-Benayas T, González-Lahoz J, Soriano V (2004) Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 18: 960-963. doi:10.1097/00002030-200404090-00019. PubMed: 15060449.

13. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S et al. (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505. doi: 10.1097/QID.0b013e328339fe53. PubMed: 20673002.

14. Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B et al. (2007) The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21: 1273-1281. doi: 10.1097/QAD.0b013e3280b7b33. PubMed: 17545703.

15. Chaisiri K, Bowonwatanuwong C, Kasetratrat N, Kiertiburanakul S (2010) Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res 8: 504-509. doi:10.2174/157016210793499259. PubMed: 21073439.

16. Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K et al. (2011) Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLOS ONE 6: e22661. doi:10.1371/journal.pone.0022661. PubMed: 21799928.

17. Nishijima T, Gatanaga H, Komatsu H, Tsukada K, Shimbo T et al. (2012) Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. PLOS ONE 7: e29977. doi:10.1371/journal.pone.0029977. PubMed: 22924194.

18. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

19. Ito J, Dung DT, Vuong MT, Tuyen do G, Vinh le D et al. (2008) Impact and perspective on chronic kidney disease in an Asian developing country: a large-scale survey in North Vietnam. Nephron Clin Pract 109: c25-c32. doi:10.1159/000134379. PubMed: 18497502.

20. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K et al. (2008) Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 52: 3144-3160. doi:10.1128/AAC.00350-08. PubMed: 18573931.

21. Gallant JE, Moore RD (2009) Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 23: 1971-1975. doi: 10.1097/QAD.0b013e32832c96e9. PubMed: 19696652.

22. Wever K, van Agtmael MA, Carr A (2010) Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 55: 78-81. doi:10.1097/QAI.0b013e3181d05579. PubMed: 20173649.

23. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK (2002) Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations Panel Clinical Practices Treat HIV MMWR Recomm Rep 51: 1-55. PubMed: 12617573.

24. Stevens LA, Levey AS (2005) Measurement of kidney function. Med Clin North Am 89: 457-473. doi:10.1016/j.mcna.2004.11.009. PubMed: 15755462.

25. Söhö W, Walker AS, Munderi P, Tugume S, Gilks CF et al. (2008) Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae. Antivir Ther 13: 761-770. PubMed: 18639777.

26. Soares AA, Eyff TF, Campani RB, Ritter L, Weinert LS et al. (2010) Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations in healthy South Brazilians. Am J Kidney Dis 55: 1162-1163. doi:10.1053/j.ajkd.2010.03.008. PubMed: 20497836.